Tempest Therapeutics Q3 2025 Financial Review
Tempest Therapeutics, Inc. (NASDAQ: TPST) has made recent headlines with its financial performance and business undertakings. As a clinical-stage biotechnology company, Tempest is focused on innovative therapies to combat cancer.
Financial Highlights of the Quarter
In the third quarter of 2025, the company reported $7.5 million in cash and cash equivalents, a decrease from $30.3 million at the end of 2024. This reduction was primarily due to cash used in operations but was somewhat offset by $4.1 million raised through a registered direct offering in June 2025, and $2.8 million from the company's at-the-market offering program.
Net Loss Overview
Tempest's net loss for the quarter was reported at $3.5 million, equating to $0.79 per share. Comparatively, in the same quarter of 2024, the company posted a net loss of $10.6 million, or $5.32 per share, indicating significant progress in cost management.
Research and Development Spending
R&D expenses were notably lower this quarter at $0.6 million versus $7.6 million during the same period last year. The reduction is primarily attributed to strategic re-prioritization of projects aimed at maximizing shareholder value.
General and Administrative Expenses
General and administrative costs remained steady at $3.0 million, consistent with the previous year's expenses. These costs are generally attributed to consulting and professional services, which are pivotal as the company streamlines its operations.
Year-to-Date Financial Performance
For the nine months ending September 30, 2025, cash used in operating activities totaled $23.2 million. The year-to-date net loss was $22.2 million with a loss per share of $5.71. Comparatively, for the same period in 2024, the figures were a net loss of $28 million and $15.48 per share.
Clinical Advancements and Future Outlook
Tempest is eagerly anticipating the initiation of the TPST-1495 Phase 2 clinical trial in partnership with the National Cancer Institute (NCI) and the Cancer Prevention Clinical Trials Network. With confidence in the potential of their investigational product, amezalpat, Tempest aims to significantly impact the treatment landscape for first-line HCC patients.
About Tempest Therapeutics
Tempest Therapeutics is dedicated to developing novel therapeutics targeting tumors through immune-mediated approaches. Through ongoing research, the company seeks to address a variety of tumors. More information about Tempest can be found on their official website.
Frequently Asked Questions
What were Tempest Therapeutics' financial results for Q3 2025?
The company reported a net loss of $3.5 million, or $0.79 per share.
How much cash did Tempest hold at the end of Q3 2025?
Tempest ended the third quarter with $7.5 million in cash and cash equivalents.
What is the focus of Tempest Therapeutics?
Tempest focuses on creating innovative therapies for cancer treatment powered by immune-mediated mechanisms.
When is the TPST-1495 Phase 2 clinical trial expected to start?
The trial is anticipated to begin soon in collaboration with the NCI and the Cancer Prevention Clinical Trials Network.
What are the current challenges facing Tempest Therapeutics?
The company is navigating cash flow management while pursuing strategic alternatives to maximize stockholder value.
